Outcomes of dental and craniofacial osseointegrated implantation in head and neck cancer patients.


Journal

Head & neck
ISSN: 1097-0347
Titre abrégé: Head Neck
Pays: United States
ID NLM: 8902541

Informations de publication

Date de publication:
09 2019
Historique:
received: 24 01 2019
revised: 11 05 2019
accepted: 04 06 2019
pubmed: 20 6 2019
medline: 19 12 2020
entrez: 20 6 2019
Statut: ppublish

Résumé

Treatment of head and neck cancer may result in disfiguring and debilitating anatomical changes. Osseointegrated implants may be used in these patients to facilitate attachment of implant-retained dentures or cosmetic prostheses. A retrospective audit was performed, reviewing the treatment of patients who received dental or craniofacial osseointegrated implants during treatment of head and neck cancer. One hundred sixty implants were inserted in 54 patients with oral, nasal, orbital, or auricular defects. Overall, 85% of implants were successful after mean follow-up of 25.7 months. The brand of implant used was shown to impart a statistically significant implant survival difference, and orbital implants had poorer survival compared to nonorbital implants. There was a statistical insignificant implant survival advantage in both nonsmokers and patients who did not undergo radiotherapy. Dental and craniofacial osseointegrated implants may be reliably used in patients with head and neck cancer. However, further research is required to clarify the role of smoking in osseointegrated implant failure.

Sections du résumé

BACKGROUND
Treatment of head and neck cancer may result in disfiguring and debilitating anatomical changes. Osseointegrated implants may be used in these patients to facilitate attachment of implant-retained dentures or cosmetic prostheses.
METHODS
A retrospective audit was performed, reviewing the treatment of patients who received dental or craniofacial osseointegrated implants during treatment of head and neck cancer.
RESULTS
One hundred sixty implants were inserted in 54 patients with oral, nasal, orbital, or auricular defects. Overall, 85% of implants were successful after mean follow-up of 25.7 months. The brand of implant used was shown to impart a statistically significant implant survival difference, and orbital implants had poorer survival compared to nonorbital implants. There was a statistical insignificant implant survival advantage in both nonsmokers and patients who did not undergo radiotherapy.
CONCLUSIONS
Dental and craniofacial osseointegrated implants may be reliably used in patients with head and neck cancer. However, further research is required to clarify the role of smoking in osseointegrated implant failure.

Identifiants

pubmed: 31215724
doi: 10.1002/hed.25845
doi:

Substances chimiques

Dental Implants 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3290-3298

Informations de copyright

© 2019 Wiley Periodicals, Inc.

Auteurs

Phillip Moore (P)

ENT/Head and Neck Unit, St Vincent's Hospital Melbourne, Victoria, Australia.

Damien Grinsell (D)

Plastic, Reconstructive, and Hand Surgery Unit, St Vincent's Hospital Melbourne, Victoria, Australia.

Bernard Lyons (B)

ENT/Head and Neck Unit, St Vincent's Hospital Melbourne, Victoria, Australia.

Ian Hewson (I)

ENT/Head and Neck Unit, St Vincent's Hospital Melbourne, Victoria, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH